# Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy

> **NCT01297101** · — · TEMPORARILY_NOT_AVAILABLE · sponsor: **Shanghai Chest Hospital**

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT01297101
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** TEMPORARILY_NOT_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2011-02-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01297101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01297101, "Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01297101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*